Description:Mouse monoclonal antibody against N-terminal sequence of human amyloid beta peptides

Purification:Protein G affinity purified

Product Type: Primary antibody

Target Protein:Human beta amyloid peptide 43

Immunogen:Full length human beta amyloid peptide 43

Fusion Myeloma:Sp2/0-Ag14

Specificity:This antibody reacts with the N-terminal peptide (DAEFRHDS) of human beta amyloid peptides and also reacts with full length human Aβ40, Aβ42 and Aβ43

Species Reacitvity:Human

Host / Isotype: Mouse, IgG2a Kappa

Formulation:Lyophilized from a solution in 0.01M PBS pH7.2

Reconstitution:Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.

Storage: Store at -20^oC

Research Area:Aging and neurodegenerative diseases

Background:

Amyloid beta peptides Aβ42 and Aβ40 have been investigated extensively for predicating Alzheimer’s disease. A recent study on amyloid beta peptide Aβ43 in brain showed that Aβ43 is more fibrillogenic than other amyloid beta peptides and could be more useful as a biomarker or therapeutic target for Alzheimer’s disease.

Since Aβ40, Aβ42 and Aβ43 are different only at the few C-end amino acids, antibody to N-terminal sequence can bind with all three amyloid beta peptides.

Application:

IHC: The picture below shows the 40x amplified brain tissue section from transgenic Alzheimer’s disease mouse model after IHC staining with clone NT 4B7.

(Procedure: After heat induced epitope retrieval, formalin-fixed paraffin-embedded brain tissue section from 12 month old APPswe/PSEN1dE9 mouse was incubated at 4^oC with 0.01mg/ml NT 4B7 overnight. Bound antibody was detected using a HRP-labeled goat anti-mouse antibody).

References:

If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.